

PO-GeP-T-656

# Preliminary Clinical Analysis with Dose-Averaged LET Calculation for Head and Neck Cancer Patients Treated by Using Carbon-Ion Radiotherapy

S.H. Lee<sup>1</sup>, A. Yamamoto<sup>1</sup>, K. Yamaoka<sup>1</sup>, E. Hotta<sup>1</sup>, M. Yamamoto<sup>1</sup>, Y. Suzuki<sup>2</sup>, A. Inomata<sup>2</sup>, M. Suga<sup>3</sup>, M. Koto<sup>1</sup> and R. Kohno<sup>1</sup>

1National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan

2Accelerator Engineering Corporation, Chiba, Japan

3Kanagawa Cancer Center, Kanagawa, Japan



### INTRODUCTION

- A new irradiation methods of optimizing dose-averaged linear energy transfer (LET<sub>d</sub>) within target, which are directly related to relative biological effectiveness (RBE), have recently been highlighted<sup>1,2</sup>.
- Clinical data are needed to determine how much LET<sub>d</sub> affects targets and normal tissues in heavy particle therapy.

#### AIM

- For head and neck cancer patients treated with carbon-ion radiotherapy (CIRT), normal tissues such as brain and optic nerves are close to the irradiation field such that those may receive radiation damage.
- In order to estimate their clinical results, a LET<sub>d</sub> calculation tool was developed. We focused on the usefulness of LET<sub>d</sub> in the clinical analysis.

#### **METHOD**

- Patient: From October 2006 to December 2013, 99 adenoid cystic carcinoma (ACC) patients treated with CIRT at National Institute of Radiological Science (NIRS, Japan) were selected (see Table 1). In-house Heavy Ion Plan (HIPLAN) treatment planning system was used in the CIRT with a wobbler-scattering method3.
- We developed the LET<sub>d</sub> and its standard deviation (LET<sub>d</sub>SD) calculation tool, and implemented in the HIPLAN:

$$LET_d(r) = rac{\sum_i (n_i imes D_i(r) imes LET_i(r))}{\sum_i (n_i imes D_i(r))}$$
  $r:$  Point of interest  $n_i:$  Number of fraction beams  $i$   $D_i(r):$  Physical dose of beam  $i$   $LET_dSD(r) = \sqrt{rac{\sum_i (n_i imes D_i(r) imes LET_i(r)^2)}{\sum_i (n_i imes D_i(r))}} - LET_d(r)^2}$   $LET_i(r):$  LET of beam

 In this study, we clinically analyzed RBE-weighted dose, LET<sub>d</sub>, and LET<sub>d</sub>SD of 99 ACCs and 128 optic nerves using the analysis tool for local control and optic neuropathy.

Table 1. Patient, treatment, and tumor and normal tissue characteristics			
Characteristics	Value (%)		
Number of patients	99	<del></del>	
Sex, Male/Female	39 (39)/60 (61)		
Age, Median/range	59/22-28		
Fractionation (fx)	16 fx (4 fx per week)		
Irradiation field, Median/range	5/22–28		
RBE-weighted dose 57.6 Gy/16 fx 64 Gy/16 fx	31 (31) 68 (69)		
Gross tumor volume (ml), Median/ range 57.6 Gy/16 fxs 64 Gy/16 fxs	46.1/1.1-255.3 38.5/2.0-193.1		
Optic nerve volume (ml), Median/range  Abbreviations: RBE = relative biological effectiveness.	1.1/0.5-2.2		
Abbi eviations. NDL - relative biological ejjectiveness.			

#### **RESULTS**




Figure 1. Volume histograms of (a) RBE-weighted dose, (b) LET<sub>d</sub>, (c) LET<sub>d</sub>SD; (d) Mean of LET<sub>d</sub> vs volume; (e) Mean of LET<sub>d</sub> vs mean of RBE-weighted dose (First row: GTV (57.6 Gy); Second row: GTV (64 Gy); Third row: Optic nerves)

Table 2. Mean and standard deviations of mean RBE-weighted dose, mean LET<sub>d</sub>, and mean LET<sub>d</sub>SD for GTV (57.6 and 64 Gy) between recurrence and non-recurrence

	GTV (57.6 Gy)	GTV (64 Gy)
RBE-weighted dose <sub>NoRecur</sub> (Gy)	56.8 ± 0.5	62.8 ± 0.4
RBE-weighted dose <sub>Recur</sub> (Gy)	56.7 ± 0.7	62.8 ± 0.4
P value	0.443	0.874
LET <sub>d,NoRecur</sub> (keV/μm)	53.3 ± 6.7	52.8 ± 4.4
$LET_{d,Recur}$ (keV/ $\mu$ m)	51.5 ± 5.2	51.3 ± 3.7
P value	0.425	0.154
LET <sub>d</sub> SD <sub>NoRecur</sub> (keV/μm)	5.7 ± 1.2	5.3 ± 1.6
$LET_dSD_{Recur}$ (keV/ $\mu$ m)	5.6 ± 2.6	5.5 ± 1.5
P value	0.961	0.541

Table 3. Mean and standard deviations of mean RBE-weighted dose, mean LET, and mean LET, SD for optic nerves between with and without optic neuropathy (ON).

	Optic nerves
RBE-weighted dose <sub>without ON</sub> (Gy)	13.2 ± 13.6
RBE-weighted Dose <sub>with ON</sub> (Gy)	33.9 ± 17.2
P value	<0.001
LET <sub>d,without ON</sub> (keV/μm)	38.3 ± 20.1
LET <sub>d,with ON</sub> (keV/μm)	53.6 ± 8.0
P value	0.006
LET <sub>d</sub> SD <sub>without ON</sub> (keV/μm)	9.4 ± 6.6
$LET_dSD_{with ON}$ (keV/ $\mu$ m)	13.6 ± 7.3
P value	0.030

## CONCLUSIONS

- For tumors, mean of LET<sub>d</sub> was not significant for recurrence and non-recurrence.
- For optic nerves, optic neuropathy occurred even at low RBE-weighted dose (10 Gy or less), when the mean of LET<sub>d</sub> was over 40 keV/µm.
- There is a need for a method to analyze LET<sub>d</sub> separately from dose. Especially, it is necessary to accurately predict the effects of high LET<sub>d</sub> at the low RBE-weighted dose.
- We will continue to analyze clinically more patients in the future

## **REFERENCES**

- 1. Tinganelli W et al. Kill-painting of hypoxic tumours in charged particle therapy. Sci Rep 2015; 5;:1-13
- 2. Inaniwa T et al. Treatment planning of intensity modulated composite particle therapy with dose and linear energy transfer optimization. Phys Med Biol 2017; 62;:5180-97
- 3. Kanematsu N et al. Treatment planning for the layer-stacking irradiation system for three-dimensional conformal heavy-ion radiotharapy. Med Phys 2002; 29;:2823-29

## **ACKNOWLEDGEMENTS**

The authors appreciate H. Oka for developing LET<sub>d</sub> analysis software and loading it into TPS, and W. Furuichi at Accelerator Engineering Corporation for his fruitful advices in calculating the dose at TPS. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Number JP19K08188).

#### **CONTACT INFORMATION**

E-mail: kohno.ryosuke@qst.go.jp